FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Thursday

 

Gilenya (Fingolimod) vs Interferon in Relapsing-Remitting Multiple Sclerosis



An international team of researchers recently reported on the results of the extension of a trial comparing fingolimod and interferon beta-1a in relapsing-remitting multiple sclerosis. Basically, patients fared better when they took fingolimod, but it’s worth examining the details.


ingolimod (Gilenya; Novartis Pharmaceuticals) is an immunomodulating drug used to help prevent symptoms of relapsing-remitting multiple sclerosis and slow the worsening of disability. It belongs to a drug class known as sphingosine l-phosphate receptor modulators and works by reducing the activation of immune cells that can cause nerve damage
.
Interferon beta-1a is a type of protein used to treat MS. It is available as Avonex and Refib and works by reducing the number of inflammatory cells that get through the blood brain barrier and modulating the expression of both pro- and anti-inflammatory factors in the brain.
The core phase was called TRANSFORMS (Trial Assessing injectable interferoN vS. FTY720 Oral in RRMS). This was a one-year, phase 3, double-blind, randomized trial that compared fingolimod (0.5 or 1.25 mg once daily) and interferon beta-1a (30 ug via intramuscular injection once a week).
This phase was followed by a long-term (up to 4.5 years) extension. During this phase, all of the patients who had been taking fingolimod continued their original treatment dose (0.5 mg for 356 patients and 1.25 mg for 330). However, those who had been taking interferon beta-1a were switched to fingolimod (0.5 mg for 167 patients, 1.25 mg for 174).
Of the 1,027 patients who entered the extended part of the study, 772 (75.2%) completed it. Here’s what the investigators found concerning the extension phase of the study:

  • The annualized relapse rate in individuals who had been taking fingolimod 0.5 mg was significantly lower than in the group that switched to fingolimod, showing a 35 percent reduced risk of relapse
  • Among those who switched to fingolimod, there was a 50 percent reduction in the annualized relapse rate, reduced activity on magnetic resonance imaging (MRI), and a lower rate of brain volume loss
  • More specifically, among those who switched to fingolimod, the T2 lesion count decreased by 63 percent and stayed low throughout the extension phase
  • The percentage of patients who were free of new or newly enlarging T2 lesions was similar between the continuous fingolimod group and those who switched (42% vs 45%, respectively)
  • The prevalence of side effects (average) was similar between the continuous fingolimod group and those who switched. Namely, common cold (averaged about 30%), lymphopenia (23%), headache (21%), urinary tract infections (11%), and upper respiratory tract infections (11%).

Story Source: The above story is based on materials provided by EMAXHEALTH
Note: Materials may be edited for content and length 
Click here to read more

Labels:



Go to Newer News Go to Older News